1
Gately Stephen T, Wanaski Stephen P: Il 13 receptor alpha 2 antibody and methods of use. Neopharm, Gately Stephen T, Wanaski Stephen P, HEFNER M Daniel, October 14, 2004: WO/2004/087758 (5 worldwide citation)

The invention provides an antiboy direted against an IL13 receptor alpha 2 (IL13-R&agr;2) and methods of using the antibody to detect an localize IL13-R&agr;2, to diagnostic a disease characterized by expression of IL13-R&agr;2, and to kill a cell that expresses an IL13-R&agr;2.


2
WANASKI Stephen, COLLINS Stephen, KINCAID John: Dérivés darylsulfonamide, compositions en contenant et leurs méthodes dutilisation, Arylsulfonamide derivatives, compositions, and methods of use. Neurotherapeutics Pharma, WANASKI Stephen, COLLINS Stephen, KINCAID John, POSORSKE Laurence H, February 9, 2012: WO/2012/018635 (5 worldwide citation)

The present invention provides acylsulfonamides including bumetanide derivatives and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these compounds and methods for their use. All of these analogs are particularly useful for the treatm ...


3
WANASKI STEPHEN: Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use. NEUROTHERAPEUTICS PHARMA, Posorske Laurence H, July 29, 2010: WO/2010/085352 (4 worldwide citation)

The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and meth ...


4
Gately Stephen, Wanaski Stephen: Silicone-substituted cox-2 selective inhibitors. Rnd Pharmaceuticals, GOULD Robert M, November 3, 2005: WO/2005/102358 (2 worldwide citation)

Novel compositions of silicon-substituted carboxylic acid-containing-nonsteroidal anti-inflammatory drugs, their preparation and use in methods for treating, preventing and/or reducing inflammation, pain, angiogenesis, and cortical dementias including Alzheimer's disease, inflammation-related cardio ...


5
WANASKI Stephen P, COLLINS Stephen D, KINCAID John, DODSON Gary Steven: [fr] DÉRIVÉS AMINÉS DHÉTÉROARYLE ET DARYLE 2,3,5 TRISUBSTITUÉS, COMPOSITIONS ET PROCÉDÉS DUTILISATION ASSOCIÉS, [en] 2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE. NEUROTHERAPEUTICS PHARMA, POSORSKE Laurence H, April 25, 2013: WO/2013/059648 (1 worldwide citation)

[en] Compounds are disclosed that have a formula represented by the following:(I) wherein Cy, L1 R1, R2a, R2b, R3, R4, n, and L2 are as described herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in ma ...


6

7
Gately Stephen, Wanaski Stephen: Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives. Rnd Pharmaceuticals, January 3, 2007: EP1737471-A2

Novel compositions of silicon-substituted carboxylic acid-containing-nonsteroidal anti-inflammatory drugs, their preparation and use in methods for treating, preventing and/or reducing inflammation, pain, angiogenesis, and cortical dementias including Alzheimer's disease, inflammation-related cardio ...


8
Hussey James, Sherman Jeff, Wanaski Stephen, Gately Stephen: Methods for dose selection of liposomal encapsulated sn38. Neopharm, Hussey James, Sherman Jeff, Wanaski Stephen, Gately Stephen, CARANGO Paul, December 15, 2005: WO/2005/117833

The present invention is directed to methods for determining pharmaceutically effective amounts of a liposomal formulation containing SN-38 (LE-SN38) by detecting polymorphisms within a uridine diphosphate glucuronosyltransferase (UGT1A1) gene. In accordance with the inventive method, LE-SN38 is adm ...


9